Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

by B2i | Dec 11, 2023 | Press Releases

ROCKVILLE, Md., Dec. 11, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”) today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to support the next...

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

by B2i | Nov 30, 2023 | Press Releases

Webcasted presentation to take place at 10:15am ET ROCKVILLE, Md., Nov. 30, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients...

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

by B2i | Nov 14, 2023 | Press Releases

ROCKVILLE, Md., Nov. 14, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a...

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

by B2i | Oct 31, 2023 | Press Releases

ROCKVILLE, Md., Oct. 31, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it...

Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

by B2i | Oct 10, 2023 | Press Releases

ROCKVILLE, Md., Oct. 10, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...